Abstract
In order to address the debatable prognostic role of MYC rearrangements in diffuse large B-cell lymphoma patients treated with rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone, we evaluated MYC rearrangements by fluorescence in situ hybridization in 563 cases using break-apart probes and IGH/MYC dual-fusion probes. Concurrent BCL2 and BCL6 aberrations were also assessed. Data were correlated with clinicopathological variables and prognostic parameters. MYC rearrangements were observed in 39/432 evaluable cases (9%), including 4 rearrangements detectable only with the dual-fusion probes, 15 detectable only with the break-apart probes and 20 detectable with both dual-fusion probes and break-apart probes. MYC rearrangements correlated with germinal center B-cell origin (P=0.02), MYC protein expression (P=0.032), and larger tumor mass size (P=0.0003). Patients with MYC rearrangements were more likely to be treatment resistant (P
Original language | English |
---|---|
Pages (from-to) | 958-971 |
Number of pages | 14 |
Journal | Modern Pathology |
Volume | 27 |
Issue number | 7 |
DOIs | |
Publication status | Published - 2014 |
Keywords
- diffuse large B-cell lymphoma
- FISH
- germinal center B-cell
- MYC
- prognosis
- rearrangement
- translocation
ASJC Scopus subject areas
- Pathology and Forensic Medicine
- Medicine(all)